Publications

> Publications

Named author:

Santos-Lima E, B’Chir S, Lane A. Combined immunogenicity data for a new DTaP-IPV-Hep B-PRP-T vaccine (Hexaxim™) following primary series administration at 2, 4, 6 months of age in Latin America.  Vaccine 2013;31:1255-1258

Thisyakorn U, Lane A. Routine newborn hepatitis B immunization. Infect Dis Clin Prac 2011;19(5):326-331

Lefèvre G, Carpenter P, Souppart C, Schmidli H, Martin JM, Lane A, Ward C, Amakye D. Interaction trial between artemether-lumefantrine (Riamet®) and quinine in healthy subjects. J Clin Pharmacol 2002:42;1147-1158

Lane AJP, Wathes DC. An electronic nose to detect changes in perineal odors associated with estrus in the cow. J Dairy Sci 1998:81;2145-2150

Lane AJP, Coombs RC, Evans DH, Levin RJ. Effect of feed interval and feed type on splanchnic haemodynamics. Arch Dis Child Fetal Neonatal Ed 1998:79;F49-F53

Lane AJP, Coombs RC, Evans DH, Levin RJ. Effect of caffeine on neonatal splanchnic blood flow. Arch Dis Child Fetal Neonatal Ed 1999:80;F128-F129

Lane A, Levin RJ. Enhanced electrogenic secretion in vitro by small intestine from glucagon-treated rats: implications for the diarrhoea of starvation. Exp Physiol 1992:77;645-648

Cited for medical writing support:

Bakhache P, Virey B, Bienenfeld C. Knowledge and practices regarding infant vaccination: results of a survey of French physicians. Eur J Ped 2018 (in press)

dos Reis D, Fraticelli L,Bassand A,Manzo-Silberman S, Peschanski N, Charpentier S, Elbaz M, Savary D, Bonnefoy-Cudraz E, Laribi S, Henry P, Guerraoui A, Tazarourte K, Chouihed T, El Khoury C. Impact of renal dysfunction on the management and outcome of acute heart failure: results from the French prospective, multicentre, DeFSSICA survey. BMJ Open (in press)

Martinón-Torres F, Diez-Domingo J, Feroldi E, Jordanov E, B’Chir S, Da Costa X. Evaluation of a hexavalent-pentavalent-hexavalent infant primary vaccination series followed by a pentavalent booster vaccine in healthy infants and toddlers. Pediatr Inf Dis J 2018 (in press) doi: 10.1097/INF.0000000000002231

Madhi S, López P, Zambrano B, Jordanov E, B’Chir S,Noriega F, Feroldi E. Antibody persistence in pre-school children after hexavalent vaccine infant primary and booster administration. Hum Vacc Immunother 2018 (in press) doi: 10.1080/21645515.2018.1546524

Julienne R, Garcin T, Crouzet E, He Z, Renault D, Thuret G, Gain P. Evaluation of corneal epithelial wound healing after penetrating keratoplasty in patients receiving a new matrix therapy agent (regenerating agent). Eur J Ophthalmol 2018 (in press) doi: 10.1177/1120672118808971

Heitzmann M, Thumm D, Baudouin C. A review of the efficacy, safety and tolerability of Lacrycon® eye drops for the treatment of dry eye syndrome. J Français d’Opthalmol 2018 (in press)

Payot F, Lachaux A, Lalanne F, Kalach N. Randomized trial of a yogurt-type amino acid-based formula in infants and children with severe cow’s milk allergy. J Ped Gastroenterol & Nutr 2018;66(1):135-140

Prymula R, Kieninger D, Feroldi E, Jordanov E, B’Chir S, DaCosta X. Immunogenicity and safety of primary and booster vaccinations of a fully liquid DTaP-IPV-HB-PRP-T hexavalent vaccine in healthy infants and toddlers in Germany and the Czech Republic. Pediatr Inf Dis J 2018;37(8):823-830

Kosalaraksa P, Chokephaibulkit K, Benjaponpitak S, Pancharoen C, Chuenkitmongkol S, B’Chir S, Da Costa X, Vidor E. Persistence of hepatitis B immune memory until 9-10 years of age following hepatitis B vaccination at birth and DTaP-IPV-HB-PRP∼T vaccination at 2, 4 and 6 months. Hum Vacc Immunother 2018;14(5):1257-1265

Doan S, Bremond-Gignac D, Chiambaretta F.Comparison of the effect of a hyaluronate-trehalose solution to hyaluronate alone on ocular surface disease index in patients with moderate to severe dry eye. Curr Med Res Opin 2018;34(8):1373-1376

Le Pen C, Palazzo L, Napoléon B. A health economic evaluation of needle-based Confocal Laser Endomicroscopy for the diagnosis of pancreatic cysts. Endosc Int Open 2017;05:E987-E995

Espul C, Benedetti L, Linares M, Cuello H, Lo Castro I, Thollot Y, Rasuli A. Seven-year follow-up of the immune response after one or 2 doses of inactivated hepatitis A vaccine given at 1 year of age in the Mendoza Province of Argentina. Hum Vacc Immunother 2017:13(11);2707-2712

Nuijts R, Mencucci R, Viaud-Quentric K, Elena P-P, Olmière C, Behndig A. Good ocular tolerance in rabbits after intracameral administration of Mydrane®, a fixed combination of tropicamide, phenylephrine, and lidocaine, with and without rinsing. J Cat Refract Surg 2017;43(5):673-679

López P, Arguedas Mohs A, Abdelnour Vásquez A, Consuelo-Miranda M, Feroldi E, Noriega F, Jordanov E, B’Chir S, Zambrano B. A randomized, controlled study of a fully liquid DTaP-IPV-HB-PRP-T hexavalent vaccine for primary and booster vaccinations of healthy infants and toddlers in Latin America. Pediatr Inf Dis J 2017;36(11):e272-e282

Ceyhan M, Yildirim I, Tezer H, Devrim I, Feroldi E. A fully liquid DTaP-IPV-HB-PRP-T hexavalent vaccine for primary and booster vaccination of healthy Turkish infants and toddlers. Turk J Med Sci 2017;47:1247-1256

Matsuoka O, Patel DM, Sasaki S, Oka H, Sasaki T, Pietrobon PJ, Laot T, Bouckenooghe A, Menezes J, de Bruyn G. Safety and immunogenicity of Clostridium difficile toxoid vaccine in Japanese adults. Jpn J Chemother 2017;65(2):183-191

Kim Y-K, Vidor E, Kim HM, Shin SM, Li K-Y, Cha S-H, Ma SH, Kim DH, Lee J, Park SE, Lee H, Kim J-D, Kim KH, Kim K-H, Kim J-H, A3L31 Study Group. Immunogenicity and safety of a fully liquid DTaP-IPV-HB-PRP∼T hexavalent vaccine compared with the standard of care in infants in the Republic of Korea. Vaccine 2017;32:4022-4028

Vesikari T, Silfverdal SA, Jordanov E, Feroldi E. A radnomized, controlled study of DTaP-IPV-HB-PRP-T, a fully liquid hexavalent vaccine, administered in a 3-, 5-, and 11- to 12-month schedule. Pediatr Inf Dis J 2017;36(1):87-93

Chiambaretta F, Doan S, Labetoulle M, Rocher N, Fekih LE, Messaoud R, Khairallah M, Baudouin C. A randomized, controlled study of the efficacy and safety of a new eyedrop formulation for moderate to severe dry eye syndrome. Eur J Ophthalmol 2017;27(1):1-9

Chhatwal J, Lalwani S, Vidor E. Immunogenicity and safety of a liquid hexavalent vaccine in Indian infants. Ind Pediatr 2017;54:15-20

Vidor E, Soubeyrand B. Manufacturing DTaP-based combination vaccines: industrial challenges around essential public health tools. Exp Rev Vaccines 2016 15(12):1575-1582

Kassianos G, Blank P, Falu-Pecurariu O, Kuchar E, Kyncl J, Ortiz de Lejarazu R, Nitsch-Osuch A, van Essen GA. Influenza vaccination: key facts for general practitioners based in Europe-a synthesis by European Experts based on national guidelines and best practices in the United Kingdom and the Netherlands. Drugs in Context 2016;5:212293

Aptel F, Choudry R, Stalmans I. Preservative-free versus preserved latanoprost eye drops in patients with open-angle glaucoma or ocular hypertension. Curr Med Res Opin 2016 Aug;32(8):1457-63

de Bruyn G, Saleh J, Workman D3, Pollak R, Elinoff V, Fraser NJ, Lefebvre G, Martens M, Mills RE, Nathan R, Trevino M, van Cleeff M, Foglia G, Ozol-Godfrey A, Patel DM, Pietrobon PJ, Gesser R; H-030-012 Clinical Investigator Study Team. Defining the optimal formulation and schedule of a candidate toxoid vaccine against Clostridium difficile infection: A randomized Phase 2 clinical trial. Vaccine. 2016 Apr 27;34(19):2170-8

Viaud-Quentric K, Lefranc-Julien S, Feraille L, Elena PP. Long-term tolerance of preservative-free eye drops containing macrogol hydroxystearate as an excipient. J Fr Ophthalmol 2016 Feb;39(2):156-63

Kim DS, Jang GC, Cha SH, Choi SH, Kim HM, Kim JH, Kang JH, Kim JH, Kim KH, Bang J, Naimi Z, Bouckenooghe A, Bosch-Castells V, Houillon G. Immunogenicity and Safety of a Booster Dose of a Live Attenuated Japanese Encephalitis Chimeric Vaccine Given 1 Year After Primary Immunization in Healthy Children in the Republic of Korea. Pediatr Infect Dis J. 2016 Feb;35(2):e60-4

Kassianos G. The importance of seasonal influenza vaccination as a travel vaccine. Journal of BGTHA 2015;XXV: 13-14

Guillemin I, Marrel A, Beriot-Mathiot A, Doucet C, Kazoglou O, Luxemburger C, Reygrobellet C, Arnould B. How do Clostridium difficile infections affect nurses’ everyday hospital work: a qualitative study. Int J Nurs Prac 2015;21 (Suppl. 2):38-45

Lobzin YV, Babachenko IV, Shamsheva OV, Tetenkova AA, Bakhareva NV, Boitsov VP, Zvereva NN. Retrospective study of the clinical epidemiological characteristics of pertussis in infants prior to their first vaccination in the Russian Federation. Inf Dis Ther 2015 doi: 10.1007/s40121-015-0059-9

Kassianos G. European healthcare workers’ willingness to be vaccinated against seasonal influenza: current situation and suggestions for improvement. Drugs in Context 2015:4;212268 doi: 10.7573/dic.212268

Guillemin I, Marrel A, Lambert J, Beriot-Mathiot A, Doucet C, Kazoglou O, Luxemburger C, Reygrobellet C, Arnold B. Patients’ experience and perception of hospital-treated Clostridium difficile infections: a qualitative study. Patient 2014: doi 10.1007/s40271-013-0043-y

Madhi SA, Koen A, Cutland C, Groome M, Santos-Lima E. Antibody persistence and booster vaccination of a fully liquid hexavalent vaccine co-administered with measles/mumps/rubella and varicella vaccines at 15-18 months of age in healthy South African infants. Pediatr Inf Dis J 2013:32(8):889-897

Eckmann C, Wasserman M, Latif F, Roberts G, Beriot-Mathiot A. Increased hospital length of stay attributable to Clostridium difficile infection in patients with four co-morbidities: an analysis of hospital episode statistics in four European countries. Eur J Health Econ 2013 (Epub ahead of print: doi 10.1007/s10198-013-0498-8)

Paterson L. The European Medicines Agency’s Article 58 procedure: reflections on the first approval for a vaccine. Regulatory Rapporteur 2013;10(4):19-23

Dutta AK, Verghese VP, Pemde H, Mathew LG, Ortiz E. Immunogenicity and safety of a DTaP-IPV//PRP~T vaccine (Pentaxim) booster dose during the second year of life in Indian children primed with the same vaccine. Ind Pediatr 2012;49:793-798

Becerra A, Gutiérrez M, Aranza C, Galán JF, Macias M, Zambrano B, Santos-Lima E. A fully liquid DTaP-IPV-Hep B-PRP-T hexavalent vaccine for primary and booster vaccination of healthy Mexican children. Vaccine 2012;30:6492-6500

Macías M, Lanata CF, Zambrano B, Gil AI, Amemiya I, Mispireta M, Ecker L, Santos-Lima E. Safety and Immunogenicity of an Investigational Fully Liquid Hexavalent: DTaP IPV Hep B PRP T Vaccine at 2, 4, 6 Months of Age Compared to Licensed Vaccines in Latin America. Pediatr Infect Dis J. 2012;31(8):e126-e132

Pancharoen C, Chotpitayasunondh T, Chuenkitmongkol S, Ortiz E. Long-term immunogenicity assessment of a DTaP-IPV//PRP-T vaccine given at 2, 4, 6 and 18-19 months of age, and immunogenicity and safety of a DTaP-IPV vaccine given as a booster dose at 4 to 6 years of age in Thai children. Southeast Asian J Trop Med Pub Health 2012;43(3):687-697

Foglia G, Shah S, Luxemburger C, Pietrobon PJF. Clostridium difficile: development of a novel candidate vaccine. Vaccine 2012;30:4307-4309

Lanata C, Zambrano B, Ecker L, Amemiya I, Gil A, Santos-Lima E. Immunogenicity and safety of a fully liquid DTaP-IPV-Hep B-PRP-T vaccine at 2-4-6 months of age in Peru. Vaccine and Vaccination 2012;3(1): dx.doi.org/10.4172/2157-7560.1000128

Chotpitayasunondh T, Thisyakorn U, Pancharoen C, Chuenkitmongkol S, Ortiz E. Antibody persistence after primary and booster doses of a pentavalent vaccine against diphtheria, tetanus, acellular pertussis, inactivated poliovirus, Haemophilus influenzae type b vaccine among Thai children at 18-19 months of age. Southeast Asian J Trop Med Pub Health 2012;43(2):442-454

Greenberg RN, Marbury TC, Foglia G, Warny M. Phase I dose finding studies of an adjuvanted Clostridium difficile toxoid vaccine. Vaccine 2012;20:2245-2249

Tregnaghi M, Zambrano B, Santos-Lima E. Antibody persistence after a primary series of a new DTaP-IPV-Hep B-PRP-T combined vaccine or separate DTaP-IPV//PRP-T and hepatitis B vaccines at 2, 4, and 6 months of age and the effect of a subsequent DTaP-IPV//PRP-T booster vaccination at 18 months of age in healthy Argentinean infants. Pediatr Infect Dis J. 2012;31(1):e24-e30

Madhi SA, Cutland C, Jones S, Groome M, Ortiz E. One-year post-primary antibody persistence and booster immune response to a DTaP-IPV//PRP~T vaccine (Pentaxim) given at 18-19 months of age in South African children primed at 6, 10 and 14 weeks of age with the same vaccine. South Afr Med J 2011;101(12):879-833

Li RC, Li FX, Li YP, Hou QM, Li CG, Li YN, Chen FS, Hu XZ, Su WB, Zhang SM, Fang HH, Ye Q, Zeng TD, Liu TX, Li XB, Huang YN, Deng ML Zhang YP, Ortiz E. Antibody persistence at 18-20 months of age and safety and immunogenicity of a booster dose of a combined DTaP-IPV//PRP~T vaccine compared to separate vaccines (DTaP, PRP~T and IPV) following primary vaccination of healthy infants in the People’s Republic of China. Vaccine 2011;29:9337-9344

Plotkin SA, Liese J, Madhi SA, Ortiz E. A DTaP IPV//PRP~T vaccine (Pentaxim™): a review of 16 years’ clinical experience. Expert Rev Vaccines. 2011;10(7):981-1005

Nates SV, Frias M, Belfiore S, Isa MB, Martinez LC, Chuit R, Armoni J, Luxemburger C. Effect on seroprevalence of anti-poliovirus antibodies and on vaccination coverage of the implementation of a DTwP-IPV-Hib vaccination programme in a South American city. Epidemiol Infect 2011;139:826-835

Tregnaghi MW, Zambrano B, Santos-Lima E. Immunogenicity and safety of an investigational hexavalent diptheria-tetanus-acellular pertussis-inactivated poliovirus-hepatitis B-Haemophilus influenzae B conjugate combined vaccine in healthy 2-, 4-, and 6-month-old Argentinean infants. Pediatr Infect Dis J 2011;30(6):e88-e96

Madhi SA, Mitha I, Cutland C, Groome M, Santos-Lima E. Immunogenicity and Safety of an Investigational Fully Liquid Hexavalent Combination Vaccine Versus Licensed Combination Vaccines at 6, 10, and 14 Weeks of Age in Healthy South African Infants. Pediatr Infect Dis J 2011;30(4):e68-e74

Kosalaraska P, Thisyakorn U, Benjaponpitak S, Chokephaibulkit K, Santos-Lima E. Immunogenicity and safety study of a new DTaP-IPV-Hep B-PRP-T combined vaccine compared to a licensed DTaP-IPV-Hep B//PRP-T comparator, both concomitantly administered with a 7-valent pneumococcal conjugate vaccine at 2, 4 and 6 months of age in Thai infants. Int J Infect Dis 2011;15(4):e249-56

Madhi SA, Cutland C, Jones S, Groome M, Ortiz E. Immunogenicity and safety of an acellular pertussis, diphtheria, tetanus, inactivated poliovirus, Hib-conjugate combined vaccine (Pentaxim™) and monovalent hepatitis B vaccine at 6, 10 and 14 weeks of age in infants in South Africa. South Afr Med J 2011;101(2):126-131

Lee SY, Hwang HS, Kim JH, Kim HH, Lee HS, Chung EH, Park SE, Ma SH, Chang JK, Guitton F, Ortiz E, Kang JH. Immunogenicity and safety of a combined diphtheria, tetanus, acellular pertussis, and inactivated poliovirus vaccine (DTaP-IPV) compared to separate administration of standalone DTaP and IPV vaccines: a randomized, controlled study in infants in the Republic of Korea. Vaccine 2011;29:1551-1557

Li RC, Li FX, Li YP, Hou QM, Li CG, Li, YN, Chen FS, Hu XZ, Su WB, Zhang SM, Fang HH, Ye Q, Zeng TD, Lu TX, Li XB, Huang YN, Deng ML, Zhang YP, Ortiz E.  Immunogenicity and safety of a pentavalent acellular pertussis combined vaccine including diphtheria, tetanus, inactivated poliovirus and conjugated Haemophilus influenza type b polysaccharide for primary vaccination at 2, 3, 4 or 3, 4, 5 months of age in infants in China. Vaccine 2011;29:1913-1920

Tregnaghi MW, Voelker R, Santos-Lima E, Zambrano B. Immunogenicity and safety of a novel yeast Hansenula polymorpha-derived recombinant Hepatitis B candidate vaccine in healthy adolescents and adults aged 10-45 years. Vaccine 2010;28(20):3595-601

Dutta A, Verghese VP, Pemde HK, Mathew LG, Ortiz E. Immunogenicity and safety of a pentavalent diphtheria, tetanus, aceullular pertussis, inactivated poliovirus, Haemophilus influenza type b conjugate combination vaccine (Pentaxim™) with hepatitis B vaccine. Ind Pediatr 2009;46:975-982